Quinazoline PI3K Inhibitors With Isoform-Selective Therapeutic Balance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for safer and more effective PI3K inhibitors for the prevention and/or treatment of cancers, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders, or neurological diseases.

Innovation Solution

Development of novel quinazoline compounds represented by specific structural formulas (I, II, III, and IV) that act as potent inhibitors of Class I PI3K isoforms, including PI3Kα, PI3Kβ, PI3Kγ, and/or PI3Kδ, with strong inhibitory activity against these targets.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing PI3K inhibitors are used, then antitumor effect is achieved, but safety issues and limited efficacy remain

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidsafety issues

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing selective inhibitors for specific PI3K isoforms (PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ) with tailored selectivity profiles. Different compounds are optimized to target specific isoforms based on their therapeutic indications, achieving localized precision in the PI3K family rather than broad non-selective inhibition.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs parameter changes by systematically varying molecular structure parameters (substituents at positions R1-R6, core scaffold modifications) to optimize the balance between potency and selectivity. This allows fine-tuning of inhibitory activity against different PI3K isoforms while maintaining safety profiles.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If broad-spectrum PI3K inhibition is achieved, then multiple disease indications are covered, but selectivity and safety are compromised

Engineering Contradiction:

Improvedisease indication coverageVSAvoidisoform selectivity

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent segments the PI3K inhibitor portfolio into distinct series targeting different isoforms (PI3Kα-selective, PI3Kβ-selective, PI3Kγ/δ-selective, and pan-PI3K inhibitors). Each series is independently optimized for its target profile, allowing selective deployment based on disease indication requirements.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent achieves universality by developing a core quinazoline scaffold that can be modified to produce inhibitors with different selectivity profiles. The same chemical platform serves multiple therapeutic indications (cancer, cardiovascular diseases, inflammatory diseases, metabolic disorders, neurological diseases) by adjusting molecular parameters.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS12508263B2Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof

Publication Date: 2025.12.30 INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI

AI summary

The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and/or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders or neurological diseases.